Data Sheet 1: Network Meta-Analysis of MASH Pharmacotherapy Efficacy and Tolerability

A systematic review and network meta-analysis of 34 Phase II/III randomized controlled trials for metabolic dysfunction-associated steatohepatitis (MASH). The document, authored by Mengshi Tang and last updated in June 2026, compares the efficacy and safety of drug classes including SGLT2 inhibitors, GLP-1 RAs, FGF21 analogs, and THR-β agonists. It reports relative risks for outcomes like fibrosis improvement and MASH resolution.

Use Cases

• Ranking drug efficacy for fibrosis improvement based on reported relative risks.
• Comparing tolerability profiles of different MASH pharmacotherapies based on safety outcomes.
• Informing clinical trial design by identifying evidence gaps highlighted in the analysis.
• Validating network meta-analysis methodologies using the described frequentist approach and sensitivity analyses.

Strengths

• Analysis is based on 34 studies from 33 unique publications, providing a defined evidence base.
• Includes specific relative risk figures with confidence intervals (e.g., RR 2.22 for FGF21 analogs).
• Employs a two-dimensional cluster analysis to evaluate the balance between efficacy and tolerability.

Limitations

• The dataset is a 852.9 KB DOCX file, suggesting limited scope and structured data content.
• Row count and column-level documentation are absent; data semantics must be inferred from the text.
• Freshness should be verified as the last update date is in the future (2026-06-04).

Provenance

Source

figshare, author Mengshi Tang

Collection Method

Systematic literature review of PubMed, Embase, Web of Science, Scopus, and Cochrane Library.

Freshness

Last updated 2026-06-04 04:30:34